[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627435":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":23,"collaborators":11,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":11,"eligibilityCriteria":33,"healthyVolunteers":34,"sex":35,"minAge":36,"maxAge":11,"enrollmentInfo":37,"targetDuration":11,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":47,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":11},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":11},"Control","NO_INTERVENTION",null,{"label":13,"type":14,"description":11,"interventionNames":15},"Progesterone","EXPERIMENTAL",[16],"Drug: Progesterone supplementation",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Progesterone supplementation","Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.",[13],{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Brittany Austin","Assistant Professor-Faculty","100627435","phase-4-progesterone-preeclampsia-100627435",false,"NCT07448597","Progesterone Preeclampsia","Progesterone Supplementation for the Prevention of Preeclampsia","Inclusion Criteria:\n\n* Pregnant individuals receiving prenatal care at participating clinics\n* \\\u003C12 weeks gestation with a viable intrauterine pregnancy\n* Age ≥18 years\n* English-speaking\n\nExclusion Criteria:\n\n* Unable or unwilling to self-administer vaginal progesterone\n* Inability or unwillingness to provide informed consent",true,"FEMALE","18 Years",{"count":38,"type":39},642,"ESTIMATED","INTERVENTIONAL",[42],"PHASE4","This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.",[45,46],"Preeclampsia","Hypertensive Disorder of Pregnancy",[13],"NOT_YET_RECRUITING","2026-05-27",{"date":51,"type":52},"2026-05-29","ACTUAL",{"date":54,"type":39},"2026-08-01",{"date":56,"type":39},"2028-05-01",{"name":5,"class":6}]